Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 4, 2023

Primary Completion Date

January 4, 2025

Study Completion Date

January 4, 2028

Conditions
Oncolytic VirusDiffuse Intrinsic Pontine GliomaAdverse Drug Event
Interventions
BIOLOGICAL

Ad-TD-nsIL12

After stereotactic biopsy, the Ommaya reservoir will be inserted through the biopsy channel and two injections of Ad-TD-nsIL12 will be delivered after surgery by Ommaya reservoir (with an interval of 3days). The interval between following injections in the subsequent treatment period will be 3 weeks ±4 days. The assigned dose for each patient will be 3x10\^9vp, 1x10\^10vp or 3x10\^10 vp suspended in 1 ml NS according to cohort design.

Trial Locations (1)

100010

RECRUITING

Sanbo Brain Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Capital Medical University

OTHER